Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up

ABSTRACT: The CAPP2 trial investigated the long-term effects of aspirin and resistant starch on cancer incidence in patients with Lynch syndrome (LS). Participants with LS were randomized double-blind to 30 g resistant starch (RS) daily or placebo for up to 4 years. We present long-term cancer outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathers, John C., Elliott, Faye, Macrae, Finlay, Mecklin, Jukka-Pekka, Möslein, Gabriela, McRonald, Fiona E., Bertario, Lucio, Evans, D. Gareth, Gerdes, Anne-Marie, Ho, Judy W.C., Lindblom, Annika, Morrison, Patrick J., Rashbass, Jem, Ramesar, Raj S., Seppälä, Toni T., Thomas, Huw J.W., Sheth, Harsh J., Pylvänäinen, Kirsi, Reed, Lynn, Borthwick, Gillian M., Bishop, D. Timothy, Burn, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433960/
https://www.ncbi.nlm.nih.gov/pubmed/35878732
http://dx.doi.org/10.1158/1940-6207.CAPR-22-0044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433960/
https://www.ncbi.nlm.nih.gov/pubmed/35878732
http://dx.doi.org/10.1158/1940-6207.CAPR-22-0044

Ejemplares similares